AFJK Stock Soars 30% Amid SEC Filings and SPAC Merger Hunt
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Aimei Health Technology Co., Ltd. (ticker: AFJK) is a blank check company listed on the NASDAQ Global Select Market under the symbol “AFJK.” Founded on April 27, 2023, and headquartered in New York, the firm is structured to pursue mergers, share exchanges, asset acquisitions, recapitalizations, or similar business combinations with healthcare-focused targets.
Corporate Structure and Experience
Aimei Health operates as a special purpose acquisition company (SPAC). The leadership team possesses expertise in healthcare innovation, finance, and mergers and acquisitions. Advisory roles and board members typically have backgrounds in investment banking, legal counsel for public offerings, and strategic partnerships within the healthcare sector. The company completed a $70 million initial public offering in mid-2023, as noted in filings by Loeb & Loeb LLP.
Healthcare SPAC by Bruno Guerrero
Recent Developments
- On December 2, 2025, and December 8, 2025, Aimei Health filed Form 8-K reports (CIK: 0001979005) with the SEC, covering material agreements and other corporate updates.
- The company’s quarterly report on Form 10-Q was filed on November 18, 2025, providing interim financial disclosures.
- On December 24, 2025, the share price increased by 30.28% to $57.3362, with trading volume of 222,466 shares.
Financial and Strategic Analysis
Aimei Health’s financial profile is characterized by early-stage metrics typical of SPACs pending a business combination. Key indicators as of December 24, 2025:
| Metric | Value |
|---|---|
| Share Price | $57.3362 (+30.28%) |
| 52-Week Range | $6.75 – $98.15 |
| Volume | 222,466 |
| Market Capitalization | $222.34 million¹ |
| P/E Ratio (TTM) | 180.15 |
| EPS (TTM) | $0.20 |
| Net Income (TTM) | $1.41 million |
| Profit Margin | 0.00% |
| Return on Assets (TTM) | –1.04% |
| Total Cash (MRQ) | $2,980 |
| Levered Free Cash Flow (TTM) | $269,620 |
¹ Intraday market cap per Yahoo Finance.
Strategically, Aimei Health aims to identify and merge with a healthcare technology business, deploying its cash reserves and capital raised. The company currently lacks a defined operating revenue stream, and future profitability will depend on the outcome of its targeted business combination. The management focus includes due diligence on prospective targets, regulatory compliance, and establishing partnerships that can deliver scalable healthcare solutions.
Market Position and Industry Context
As a blank check company in the healthcare sector, Aimei Health competes for investor attention with other SPACs and established health technology firms. Its NASDAQ listing enhances visibility but also subjects it to market volatility, as evidenced by its wide 52-week price range. Industry trends favor digital health services, telemedicine platforms, and biotech innovations—areas where Aimei Health may seek its merger partner. Until a definitive business combination is announced, the company’s valuation and investor sentiment will depend on deal flow prospects and broader equity market performance.
tl;dr
On December 24, 2025, AFJK shares increased by 30.28% to $57.3362 on volume of 222,466 amid ongoing SEC filings (Forms 8-K on December 2 and 8) and a November 18 Form 10-Q. With a market cap near $222 million and no operating revenue yet, Aimei Health Technology is in search of a healthcare technology target. The next significant event will be the announcement of a definitive merger agreement.